Anterior segment uses of bevacizumab

Current Opinion in Ophthalmology

Volumn 23, Issue 4, 2012, Pages 303-316

  Bahar, Irit ^a   Yeung, Sonia N ^b   Sella, Ruti ^a   Slomovic, Allan ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

bevacizumab; corneal neovascularization; iris neovascularization; neovascular glaucoma

Indexed keywords

BETAMETHASONE; BEVACIZUMAB; DEXAMETHASONE SODIUM PHOSPHATE; EYE DROPS; PEGAPTANIB; RANIBIZUMAB; SUNITINIB; TRASTUZUMAB; TRIAMCINOLONE; VERTEPORFIN;

ANTERIOR EYE SEGMENT; ARTICLE; CORNEA DISEASE; CORNEA EROSION; CORNEA NEOVASCULARIZATION; CORNEA THINNING; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; EPITHELIOPATHY; EYE DISEASE; HUMAN; IRIS DISEASE; NEOVASCULAR GLAUCOMA; NONHUMAN; PRIORITY JOURNAL; PTERYGIUM; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTERIOR EYE SEGMENT; ANTIBODIES, MONOCLONAL, HUMANIZED; GLAUCOMA, NEOVASCULAR; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862514403     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e3283548459     Document Type: Article

References (120)

1. Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-1934.
2. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39:18-22.
3. Adamis AP, Shima DT, Tolentino M, et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch Ophthalmol 1996; 114:66-71.
4. Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability actor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.
5. D'Amore PA. Mechanisms of retinal and choroidal neovascularization. Invest Ophthalmol Vis Sci 1994; 35:3974-3979.
6. Ferrara, N, Leung, DW, Phillips, HS. Molecular characterization and distribution of vascular endothelial growth factor. In: Muller, EE MacLeod, RB, editors. Neuroendocrine perspectives 9127. New York: Springer-Verlag; 1991.
7. Kenyon, BM, Voest, EE, Chen, CC, et al. A model of angiogenesis in the mouse cornea Invest Ophthalmol Vis Sci 137:1625-1632.
8. Phillips GD, Stone AM, Jones BD, et al. Vascular endothelial growth factor (rh VEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 1994; 8:961-966.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331:1480-1487.
10. Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995; 73:333-346.
11. Breier G, Albrecht U, Sterrer S, et al. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114:521-532.
12. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/ vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145:574-584.
13. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72:645-683.
14. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114:964-970.
15. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41:2514-2522.
16. Lee DH, Cho HJ, Kim JT, et al. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001; 20:738-742.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:335-2342.
18. Phillips K, Arffa R, Cintron C, et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983; 101:640-643.
19. Murata M, Shimizu S, Horiuchi S, et al. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2006; 244:205-209.
20. Riazi-Esfahani M, Peyman GA, Aydin E, et al. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea 2006; 25:801-805.
21. Benelli U, Ross JR, Nardi M, et al. Corneal neovascularization induced by xenografts or chemical cautery: inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 1997; 38:274-282.
22. Joussen AM, Kruse FE, Volcker HE, et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 1999; 237:920-927.
23. Ambati BK, Joussen AM, Ambati J, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120:1063-1068.
24. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001; 75:9828-9835.
25. Pé rez-Santonja JJ, Campos-Mollo E, Lledó-Riquelme M, et al. Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and Sunitinib (anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010; 150:519-528; e1.
26. Habot-Wilner Z, Barequet IS, Ivanir Y, et al. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 2010; 88:862-867.
27. Sener E, Yuksel N, Yildiz DK, et al. The impact of subconjunctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res 2011; 36:1005-1013. In this experimental study, bevacizumab, ranibizumab, pegaptanib, and trastuzumab were found effective for the inhibition of corneal NV in a rat model, with bevacizumab shown to be the most effective agent.
28. Mello GR, Pizzolatti ML, Wasilewski D, et al. The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model. Clinics (Sao Paulo) 2011; 66:1443-1450.
29. Chalam KV, Agarwal S, Brar VS, et al. Evaluation of cytotoxic effects of bevacizumab on human corneal cells. Cornea 2009; 28:328-333.
30. Bock F, Onderka J, Rummelt C, et al. Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 2009; 50:2095-2102.
31. Kim TI, Chung JL, Hong JP, et al. Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 2009; 50:4653-4659.
32. Yoeruek E, Ziemssen F, Henke-Fahle S, et al. Bevacizumab Study Group. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008; 86:322-328.
33. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009; 127:381-389.
34. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115:33-38.
35. Chu HS, Hu FR, Yang CM, et al. Subconjunctival injection of bevacizumab in the treatment of corneal neovascularization associated with lipid deposition. Cornea 2011; 30:60-66. In this case interventional study, subconjunctival injection of bevacizumab was found effective as a treatment for patients who had corneal NV associated with lipid keratopathy.
36. Jeong JH, Chun YS, Kim ES, et al. Compensatory growth factor and cytokine response in tears after subconjunctival bevacizumab injection. Cornea 2011; 30:1071-1077.
37. Foroutan A, Fariba B, Pejman B, et al. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty. Cornea 2010; 29:1268-1272.
38. Su W, Li Z, Li Y, et al. Doxycycline enhances the inhibitory effects of bevacizumab on corneal neovascularization and prevents its side effects. Invest Ophthalmol Vis Sci 2011 [Epub ahead of print].
39. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:1375-1382.
40. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008; 27:992-995.
41. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27:142-147.
42. Dastjerdi MH, Sadrai Z, Saban DR, et al. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011; 52:8718-8723. This study demonstrates that subconjunctivally injected bevacizumab in mice eyes with an intact cornea penetrates well into the corneal stroma.
43. Hashemian MN, Z-Mehrjardi H, Moghimi S, et al. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic Res 2011; 46:50-54. This experimental study demonstrates that both subconjunctival and topical bevacizumab can prevent corneal neovascularization in rats following corneal chemical injury.
44. Vassileva PI, Hergeldzhieva TG. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol 2009; 247:1701-1706.
45. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 2009; 28:1070-1073.
46. Yeung SN, Lichtinger A, Kim P, et al. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 2011; 30:1110-1114.
47. Georgakopoulos CD, Vasilakis P, Makri OE, et al. Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse. Cutan Ocul Toxicol 2011; 30:320-322.
48. Hashemian MN, Zare MA, Rahimi F, et al. Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea 2011; 30:215-218.
49. Avisar I, Weinberger D, Kremer I. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model. Curr Eye Res 2010; 35:108-115.
50. Dratviman-Storobinsky O, Lubin BC, Hasanreisoglu M, et al. Effect of subconjunctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. Mol Vis 2009; 15:2326-2338.
51. Mackenzie SE, Tucker WR, Poole TR. Bevacizumab (avastin) for corneal neovascularization: corneal light shield soaked application. Cornea 2009; 28:246-247.
52. Hoffart L, Matonti F, Conrath J, et al. Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone. Clin Experiment Ophthalmol 2010; 38:346-352.
53. Kang S, Chung SK. The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits. Cornea 2010; 29:192-196.
54. You IC, Im SK, Lee SH, et al. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea 2011; 30:30-33.
55. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008; 27:1195-1199.
56. Qian CX, Bahar I, Levinger E, et al. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008; 27:1090-1092.
57. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 1996; 98:195-201.
58. Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol 1998; 236:702-708.
59. Powers MR, Qu Z, O'Brien B, et al. Immunolocalization of bFGF in pterygia: association with mast cells. Cornea 1997; 16:545-549.
60. Lee JK, Song YS, Ha HS, et al. Endothelial progenitor cells in pterygium pathogenesis. Eye 2007; 21:1186-1193.
61. Jin J, Guan M, Sima J, et al. Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003; 22:473-477.
62. Enkvetchakul O, Thanathanee O, Rangsin R, et al. A randomized controlled trial of intralesional bevacizumab injection on primary pterygium: preliminary results. Cornea 2011; 30:1213-1218. This is a randomized controlled trial showing that intralesional bevacizumab injection may be a well tolerated and effective treatment for primary pterygium.
63. Banifatemi M, Razeghinejad MR, Hosseini H, et al. Bevacizumab and ocular wound healing after primary pterygium excision. J Ocul Pharmacol Ther 2011; 27:17-21. In this randomized, double-blinded, placebo-controlled study, subconjunctival bevacizumab injections did not have adverse effects on early postoperative wound healing of excised primary pterygium.
64. Shenasi A, Mousavi F, Shoa-Ahari S, et al. Subconjunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial. Cornea 2011; 30:1219-1222. This is the first clinical trial to investigate the effect of an immediate subconjunctival bevacizumab injection after excision of primary pterygium; it demonstrates good tolerance; however, there is no significant influence over recurrence rate.
65. Fallah MR, Khosravi K, Hashemian MN, et al. Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 2010; 35:17-22.
66. Fallah Tafti MR, Khosravifard K, Mohammadpour M, et al. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 2011; 30:127-129. This study shows that intralesional bevacizumab injection may be effective in reducing the size of pterygium.
67. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008 33:23-28.
68. Besharati MR, Manaviat MR, Souzani A. Subconjunctival bevacizumab injection in treatment of pterygium. Acta Med Iran 2011; 49:179-183. This interventional case series demonstrates that subconjunctival bevacizumab injection is both useful and safe for the treatment of primary or recurrent pterygium.
69. Saxena S, Vishwkarma K, Khattri M, et al. Multiple subconjunctival bevacizumab for advanced primary pterygium. Ann Ophthalmol (Skokie) 2010; 42:28-30.
70. Lekhanont K, Patarakittam T, Thongphiew P, et al. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 2011 [Epub ahead of print]. In this study the authors report that a single subconjunctival bevacizumab injection may only partially and transiently decrease conjunctival vascularization in impending recurrent pterygium, with no beneficial effect regarding regression or recurrence rate.
71. Wu PC, Kuo HK, Tai MH, et al. Topical bevacizumab eyedrops for limbalconjunctival neovascularization in impending recurrent pterygium. Cornea 2009; 28:103-104.
72. Wand M. Treatment of neovascular glaucoma. Ann Ophthalmol 1979; 11:1557-1559.
73. Sivak-Callcott JA, O'Day DM, Gass JD, et al. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology 2001; 108:1767-1776; quiz1777, 1800.
74. Allingham RA, Damji KF, Freedman S, et al. Glaucomas associated with disorders of the retina, vitreous and choroid. 5th ed. Shields' textbook of glaucoma. Philadelphia: Lippincott, Williams and Wilkins; 2005.
75. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009; 24:113-121.
76. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112:806-816.
77. Moraczewski AL, Lee RK, Palmberg PF, et al. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol 2009; 93:589-593.
78. Duker JS, Brown GC. The efficacy of panretinal photocoagulation for neovascularization of the iris after central retinal artery obstruction. Ophthalmology 1989; 96:92-95.
79. Grisanti S, Biester S, Peters S, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142:158-160.
80. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol 2011; 129:145-150.
81. Kocak Altintas AG, Arifoglu HB, Tutar E, et al. Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. Cutan Ocul Toxicol 2011 [Epub ahead of print]. This study demonstrates a significant reduction of NV shortly after the injection of bevacizumab to the posterior chamber combined with set-on implantation in patients with NVG, thus preventing the failure of filtration procedure.
82. Chalam KV, Gupta SK, Grover S, et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008; 18:255-262.
83. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115:1571- 1580; 1580 e1-3.
84. Jiang Y, Liang X, Li X, et al. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta Ophthalmol 2009; 87:736-740.
85. Beutel J, Peters S, Luke M, et al. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2010; 88:103-109.
86. Wolf A, von Jagow B, Ulbig M, et al. Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica 2011; 226:51-56.
87. Sasamoto Y, Oshima Y, Miki A, et al. Clinical outcome and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study. J Ocul Pharmacol Ther 2012; 28:41-48. This study compares low doses with high doses of intravitreally injected bevacizumab for the treatment of NVG, showing that a low-dose regime may be as effective as the currently accepted higher dose regime.
88. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142:1054-1056.
89. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006; 37: 144-146.
90. Mason JO 3rd, Albert MA Jr, Mays A, et al. Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 2006; 26:839-841.
91. Gheith ME, Siam GA, de Barros DS, et al. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23:487-491.
92. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007; 35:494-496.
93. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007; 16:437-439.
94. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26:354-356.
95. Oshima Y, Sakaguchi H, Gomi F, et al. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142:155-158.
96. Grover S, Gupta S, Sharma R, et al. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009; 93:273-274.
97. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26:352-354.
98. Jonas JB, Golubkina L, Libondi T, et al. Intravitreal bevacizumab for neovascular glaucoma. Acta Ophthalmol 2010; 88.
99. Duch S, Buchacra O, Milla E, et al. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma 2009; 18: 140-143.
100. Ehlers JP, Spirn MJ, Lam A, et al. Combination intravitreal bevacizumab/ panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008; 28:696-702.
101. Mermoud A, Salmon JF, Alexander P, et al. Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome. Ophthalmology 1993; 100:897-902.
102. Pastor SA, Singh K, Lee DA, et al. Cyclophotocoagulation: a report by the American Academy of Ophthalmology. Ophthalmology 2001; 108:2130-2138.
103. Eid TM, Radwan A, el-Manawy W, et al. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol 2009; 44:451-456.
104. Takihara Y, Inatani M, Fukushima M, et al. Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure. Am J Ophthalmol 2009; 147:912-918; 918 e1.
105. Chen CH, Lai IC, Wu PC, et al. Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma. J Ocul Pharmacol Ther 2010; 26:111-118.
106. Saito Y, Higashide T, Takeda H, et al. Beneficial effects of preoperative intravitreal bevacizumab on trabeculectomy outcomes in neovascular glaucoma. Acta Ophthalmol 2010; 88:96-102.
107. Takihara Y, Inatani M, Kawaji T, et al. Combined intravitreal bevacizumab and trabeculectomy with mitomycin C versus trabeculectomy with mitomycin C alone for neovascular glaucoma. J Glaucoma 2011; 20:196-201. The authors of this study report that adding intravitreal bevacizumab injection to trabeculectomy with mitomycin C may reduce hyphema and provide a further IOP reduction in the immediate post operative period, without favorable effects on longterm surgical outcomes.
108. Alkawas AA, Shahien EA, Hussein AM. Management of neovascular glaucoma with panretinal photocoagulation, intravitreal bevacizumab, and subsequent trabeculectomy with mitomycin C. J Glaucoma 2010; 19:622-626.
109. Elgin U, Berker N, Batman A, et al. Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. J Glaucoma 2006; 15:466-470.
110. Miki A, Oshima Y, Otori Y, et al. Efficacy of intravitreal bevacizumab as adjunctive treatment with pars plana vitrectomy, endolaser photocoagulation, and trabeculectomy for neovascular glaucoma. Br J Ophthalmol 2008; 92:1431-1433.
111. Cornish KS, Ramamurthi S, Saidkasimova S, et al. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye (Lond) 2009; 23:979-981.
112. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 2007; 39:121-122.
113. Coote MA, Ruddle JB, QinQ, et al. Vascular changes after intra-bleb injection of bevacizumab. J Glaucoma 2008; 17:517-518.
114. Sugimoto Y, Mochizuki H, Okumichi H, et al. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010; 248:1601-1609.
115. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol 2009; 19:607-612.
116. Gupta V, Jha R, Rao A, et al. The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. Eur J Ophthalmol 2009; 19:435-441.
117. Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009; 18:632-637.
118. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007; 26:977-982.
119. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146:508-512.
120. Marey HM, Ellakwa AF. Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. Clin Ophthalmol 2011; 5:841-845.